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Abstract
Two-pore domain potassium (K2P) channels are responsible for background potassium (K+) 
current, which is crucial for the maintenance of resting membrane potential. K2P18.1, also called 
TWIK-related spinal cord K+ channel (TRESK) or KCNK18, is thought to be a major contributor 
to background K+ currents, particularly in sensory neurons where it is abundantly expressed. 
Despite its critical role and potential therapeutic implication, pharmacological tools for probing 
K2P18.1 activity remain unavailable. Here, we report a high-throughput screen against a collection 
of bioactive compounds that yielded 26 inhibitors and 8 activators of K2P18.1 channel activity 
with more than 10-fold selectivity over the homologous channel K2P9.1. Among these modulators, 
the antihistamine loratadine inhibited K2P18.1 activity with IC50 of 0.49 ± 0.23 μM and is 
considerably more potent than existing K2P18.1 inhibitors. Importantly, the inhibition by 
loratadine remains equally efficacious upon potentiation of K2P18.1 by calcium signaling. 
Furthermore, the loratadine effect is dependent on transmembrane residues F145 and F352, 
providing orthogonal evidence that the inhibition is caused by a direct compound-channel 
interaction. This study reveals new pharmacological modulators of K2P18.1 activity useful in 
dissecting native K2P18.1 function.
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While many forms of cellular ionic current are dependent upon membrane voltage, K+ 
background, or “leak”, current is voltage independent and crucial for maintenance of resting 
membrane potential. The molecules responsible for this background K+ current are the two-
pore domain potassium (K2P) channels. The K2P family currently consists of 15 members 
divided into six subfamilies (Enyedi and Czirjak, 2010).
K2P18.1 (or TRESK) is a member of the K2P family and resides in a subfamily of its own. 
K2P18.1 stands apart from the other K2P channels for several reasons, most prominently for 
its calcium-dependent augmentation. Unlike classical calcium-activated K+ channels, 
calcium’s effect is not caused by direct binding of calcium to the channel but via the activity 
of the serine/threonine phosphatase, calcineurin (Czirjak and Enyedi, 2006; Czirjak et al., 
2004). Other proteins involved in regulation of K2P18.1 include scaffolding 14-3-3 proteins 
and protein kinase A (Enyedi et al., 2012).
K2P18.1 is found primarily in dorsal root ganglion (DRG) and trigeminal ganglion (TG) 
neurons and was reported to be a major contributor to background current in DRG neurons 
(Kang and Kim, 2006; Lafreniere et al., 2010). In addition to its important roles in peripheral 
sensory neurons, human genetics studies have recently shown that a dominant-negative 
mutation in K2P18.1 found in patients is directly linked to familial migraine with aura 
(Lafreniere et al., 2010). This mutation was shown to induce neuronal hyperexcitability 
when expressed in TG neurons (Liu et al., 2013). These studies contribute to emerging 
evidence that K2P18.1 plays an important role in pain-related disorders, and raise the 
possibility of developing K2P18.1 modulators to achieve therapeutic benefits.
To date, several compounds are known to have K2P18.1 modulatory activity (Kang et al., 
2008; Tulleuda et al., 2011). Like many K2P channels, K2P18.1 activity is enhanced by 
application of volatile anesthetics such as isoflurane. The local anesthetic lidocaine was 
shown to inhibit human K2P18.1 with half-maximal inhibitory concentration (IC50) of 3.4 
mM (Liu et al., 2004). In addition, two compounds appear to display certain selectivity for 
K2P18.1 over other K2P family members. The sodium channel blocker lamotrigine was 
shown to inhibit mouse K2P18.1 specifically over K2P10.1 with an IC50 of 47 μM (Kang et 
al., 2008). Isobutylalkenyl amide (IBA), a derivative of hydroxyl-α-sanshool, was shown to 
inhibit mouse K2P18.1 by approximately 70% at a concentration of 500 μM but displayed no 
inhibitory activity against K2P2.1, K2P10.1, or K2P4.1 at this concentration (Tulleuda et al., 
2011).
The purpose of this study was to search for better small-molecule modulators of K2P18.1 
that directly target the channel. This was pursued by first screening the Library of 
Pharmacologically Active Compounds (LOPAC) against the K2P18.1 channel using a 
fluorescent-based assay. This was followed by a counter screen to separate compounds with 
or without activity against the homologous channel K2P9.1. Compounds of sufficient 
selectivity and potency were then chosen for further validation and characterization using 
both the fluorescent-based assay and electrophysiology. Critical residues for conferring drug 
sensitivity were investigated using wild type and mutant channels.
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2. Materials and Methods
2.1 Cell Culture and Transfection
HEK293 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) and 2 mM L-Glutamine. HEK293-K2P9.1 stable cell 
lines were previously generated (Miller et al., 2012) and K2P9.1 expression was induced by 
incubation with 1 μM tetracycline for 16 h. These cells were cultured in DMEM 
supplemented with 10% FBS, 2 mM L-Glutamine, 400 μg/ml hygromycin, and 15 μg/ml 
blasticidin. All cells were maintained at 37°C in 5% CO2.
To express K2P18.1 channels (encoded by the KCNK18 gene), HEK293 cells were 
transfected using either FuGENE 6® transfection reagent (Promega, Madison WI) or via 
electroporation using the MaxCyte platform. Cells were transfected with both human 
K2P18.1 cDNA (OriGene Technologies, Rockville, MD) and either GFP or mCherry. 
Experiments were performed 24–48 h after transfection.
2.2 Compounds
All compounds for the primary screening and follow-up analysis were purchased from 
Sigma-Aldrich (St. Louis, MO). The Library of Pharmacologically Active Compounds 
(LOPAC) consists of 1,280 small molecules with well-characterized biological activities. 
The library was kept at 10 mM in DMSO. Loratadine (4-(8-Chloro-5,6-dihydro-11H-
benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester) and 
carbachol (carbamoylcholine chloride, (2-Hydroxyethyl)trimethyl-ammonium chloride 
carbamate) were dissolved in DMSO to a stock concentration of 50 mM. Lidocaine (2-
Diethylamino-N-(2,6-dimethylphenyl)acetamide) was dissolved in saline to a stock 
concentration of 200 mM.
2.3 Thallium-Flux Assays
For the primary screen, HEK293 cells transfected with human K2P18.1 were used. Un-
transfected cells served as a negative control. An equal number of cells (7,000 cells/50 μl) 
were added to each well of 384-well assay plates (BD polylysine-precoated, San Jose, CA). 
Cells were maintained at 37°C in 5% CO2 for 18 h before the assay. For assay, cells were 
loaded with FluxOR™ Tl+-sensitive dye (Life Technologies, Grand Island, NY) for 90 min 
in the dark at room temperature. Following this, dye containing buffer was replaced with a 
buffer containing 1X Hank’s balanced salt solution (with Ca2+ and Mg2+), 20 mM HEPES, 
and 0.77 mg/ml probenecid. Library compounds were added 20 min prior to Tl+ stimulation. 
The plate was loaded onto a FDSS 6000 (Hamamastu, Middlesex, NJ) and a baseline was 
established after 10 s fluorescent signal detection. Then, 5X stimulus buffer containing 1X 
chloride-free buffer (Life Technologies), 25mM K2SO4, and 7.5mM Tl2SO4 was added, and 
fluorescence signal continued to be detected for 140 s. The counter screen utilized the same 
assay technique as reported (Miller et al., 2012) with tetracycline induced HEK293-K2P9.1 
cells plated at 15,000 cells/50μl. Transfected or induced cells stimulated with buffer only 
were used as positive controls. Un-transfected or noninduced cells stimulated with buffer 
only were used as negative controls. To evaluate assay quality, Z′ factor was calculated as 
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described (Zhang et al., 1999) using fluorescence intensity at 100 s for inhibitors and 50 s 
for activators.
Potential inhibitory effect was assessed by measuring the fluorescence intensity at 100 s and 
potential activation effect was assessed by measuring fluorescence intensity at 50 s (see Fig. 
S2). Fluorescence change was calculated and activity was normalized using the B scores 
method as reported (Brideau et al., 2003) to evaluate compound effects. Compared to buffer 
controls, a compound that caused more than 2.25 S.D. increase in activity was defined as an 
activator; a compound that caused more than 3 S.D. reduction in activity was defined as an 
inhibitor.
In the validation assays, compounds were tested in a 10-point 1:3 gradient in quadruplicate 
with the highest concentration at 30 μM. In the characterization assays, lidocaine was tested 
in a 10-point 1:2 gradient in triplicate and loratadine was tested in a 10-point 1:3 gradient in 
quadruplicate with the highest concentrations at 20 mM and 150 μM respectively.
2.4 Site-directed Mutagenesis
Mutant K2P18.1 (mutK2P18.1) was generated using a QuikChange Lightning site-directed 
mutagenesis kit (Agilent Technologies, Santa Clara, CA) according to the provided protocol. 
F145A/F352A double mutant was generated from successive single mutations and mutant 
K2P18.1 DNA was confirmed by sequencing.
2.5 Manual Electrophysiological Studies
HEK293 cells heterologously expressing wild type K2P18.1 (HEK293-wtK2P18.1), those 
expressing mutant K2P18.1 (HEK293-mutK2P18.1), or those expressing K2P9.1 (HEK293-
K2P9.1) were seeded onto poly-l-lysine coated coverslips one day before recordings were 
performed. For cells transfected with K2P18.1, only cells expressing GFP or mCherry were 
selected for recording. Pipettes were pulled from micropipette glass (World Precision 
Instruments Inc., Sarasota, FL) to 2–4 MΩ when filled with a pipette solution containing 145 
mM KCl, 1 mM MgCl2, 10 mM HEPES, 5 mM EGTA, 5 mM MgATP, pH 7.25 and placed 
in a bath solution containing 140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1.5 mM MgCl2, 10 
mM HEPES, 10 mM Glucose, pH 7.35. Isolated cells were voltage-clamped in the whole-
cell configuration using a patch clamp amplifier Axopatch 200B (Molecular Devices, 
Sunneyvale, CA). Currents were filtered at 1 kHz, digitized at 10 kHz, and acquired with 
pClamp 9 software. The holding potential was −80 mV. The voltage protocol consisted of a 
50 ms step to −120 mV, a 500 ms ramp from −120 mV to +60 mV, a 500 ms step to −80 
mV, and finally a 500 ms step to +60 mV. This protocol was repeated every 5 s. 
Representative current traces were taken from the 500 ms ramp. Current was measured at 
the end of the +60 mV step to determine extent of compound inhibition. Data was analyzed 
with Clampfit 9 (Molecular Devices).
2.6 Statistical analyses
Sigmoidal fitting, linear fitting, and EC50/IC50 value determination were performed using 
Origin 6.0 (OriginLab, Northampton, MA). Data are expressed as mean ± S.D. Statistical 
significance was determined using Student’s t-test for independent samples.
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3.1 Screening for Specific Modulators of K2P18.1 Channel Activity
As most K+ channels are permeable to Tl+, pre-loading with a fluorescent Tl+-sensitive dye 
allows for an increase in intracellular Tl+ concentration to be used as a surrogate readout of 
channel activity with attractive signal to noise ratio (Weaver et al., 2004). Using a 
commercial fluorescence-based Tl+ flux assay, the bioactive LOPAC collection compounds 
were tested at 10 μM in duplicate against HEK293 cells expressing human K2P18.1 
(HEK293-K2P18.1) to look for small-molecule modulators of K2P18.1 channel activity. A 
good correlation was observed between replicates with R = 0.96 (Fig. S1) and Z′ factors of 
0.79 ± 0.05 for activators and 0.79 ± 0.04 for inhibitors. The assay is therefore of sufficient 
quality for reliable hit identification. Compared to buffer controls, compounds that increased 
fluorescence intensity by more than 2.25 S.D. were selected as activator hits while those that 
decreased fluorescence intensity by more than 3 S.D. were selected as inhibitor hits. Based 
on these criteria, the hit rate was 0.94% for activators and 2.19% for inhibitors. In order to 
profile target selectivity of active compounds, a parallel counter screen was performed using 
the same library under identical conditions against HEK293 cells expressing human K2P9.1 
(HEK293-K2P9.1). Compound activity against both K2P channels was compared and is 
plotted in Fig. 1B and 1C. Those compounds with preference for K2P18.1 were selected for 
further validation. Experimental outline is diagramed in Fig. 1A.
3.2 Validation of Compound Activity and Determination of Potency and Efficacy
To confirm the activity of the selected compounds and to estimate their potency, a validation 
assay was performed on all K2P18.1-selective compounds. We tested concentrations ranging 
from 1.5 nM to 30 μM for each compound against both HEK293-K2P18.1 cells and 
HEK293-K2P9.1 cells. The potencies and efficacies of all activators and inhibitors are 
summarized in Table 1 and Table 2. In total, 26 inhibitors and 8 activators were confirmed 
with half maximal effective concentration below 30 μM and better than 10-fold specificity 
for K2P18.1 over K2P9.1.
The identified inhibitors are bioactive and some are known to have diverse activities. Fig. 2 
shows the structures of these active compounds, which include the antibiotic oligomycin A 
(IC50=3.71 ± 0.82 μM), the CB2 cannabinoid receptor agonist JWH-015 (IC50=5.47 ± 0.37 
μM), the thromboxane A2 receptor antagonist L-655,240 (IC50=7.35 ± 0.47 μM), and the 
antihistamine loratadine (IC50=0.69 ± 0.06 μM). Few identified inhibitors have any 
connection to each other in terms of their known mechanisms of action, and none have been 
previously shown to have any activity against K2P18.1 (Hall et al., 1987; Kreutner W, 1987; 
Lombard et al., 2007; Salomon AR, 2001). Among the inhibitors, the antihistamine 
loratadine displayed considerable potency and selectivity and was therefore chosen for 
further characterization studies to explore its mechanism of action.
3.3 Characterization of Loratadine Activity on K2P18.1
To investigate the activity of loratadine on K2P18.1, we compared its pharmacological 
characteristics with that of a known, but non-selective, K2P18.1 pore blocker, lidocaine 
(Kim et al., 2013; Liu et al., 2004). We first tested whether loratadine may exert its effects 
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via modulation of receptor signaling pathways, consequently down-regulating channel 
activity. We employed a Tl+ flux assay to determine the effects of inhibitors in the presence 
and absence of carbachol, which activates K2P18.1 via its activation effect on endogenous 
muscarinic G-protein coupled receptors in HEK293 cells (Table 2 and Luo et al., 2008). In 
these experiments, 30μM carbachol, a concentration known to activate K2P18.1 activity, was 
employed to turn on endogenous M receptors (Braun et al., 2011). Thallium-induced 
fluorescent responses were recorded, and the signal intensity was normalized to give rise to 
concentration-response curves (Fig. 3). The IC50 values for lidocaine with and without 
carbachol were 3.41 ± 0.57 mM and 3.65 ± 0.38 mM, respectively. These results are 
consistent with previously reported values for lidocaine activity and with its pore blocking 
mechanism (Kim et al., 2013; Liu et al., 2004). The IC50 values for loratadine with and 
without carbachol were 0.66 ± 0.02 μM and 0.69 ± 0.06 μM, respectively. As with lidocaine, 
loratadine showed virtually identical potencies and efficacies independent of channel 
activation. These data argue favorably that the primary action of loratadine, similar to 
lidocaine, is not through modulating a signaling pathway to down regulate the channel 
activity but rather through a direct interaction with K2P18.1 channels.
Admittedly, G-protein coupled receptor signaling is one of several pathways that could 
modulate K2P18.1 activity and the Tl+-based flux measurement applied here is an endpoint, 
accumulative readout. In order to more directly monitor compound effects on ionic current, 
activity of recombinantly expressed K2P18.1 in HEK293 cells was measured using whole-
cell patch clamp recording in compound-free conditions and in the presence of either 1 mM 
lidocaine or 10 μM loratadine. The membrane potential of cells was held at −80 mV, 
followed by a ramp from −120 mV to +60 mV over a duration of 500 ms, then a step to +60 
mV. Un-transfected cells showed small background currents (<200 pA at +60 mV, data not 
shown). However, transfected cells resulted in large currents (>1,000 pA at +60 mV, Fig. 
4A) with outward rectification. Fig. 4A shows representative traces of the ramp protocol 
from cells exposed to each compound. 1 mM lidocaine and 10 μM loratadine inhibited wild 
type K2P18.1 (wtK2P18.1) by 65.2 ± 10.4% (n=5) and 87.5 ± 3.7% (n=5), respectively. 
Loratadine was then tested at 3 more concentrations, 0.1 μM, 1 μM, and 50 μM to test its 
concentration-dependent effects (Fig. 4C). The IC50 of loratadine against K2P18.1 was 0.49 
± 0.23 μM (n ≥ 4). To validate its selectivity for K2P18.1, loratadine was tested at the same 
concentrations against K2P9.1 using tetracycline induced HEK293-K2P9.1 cells (Fig. 4C). 
The IC50 of loratadine against K2P9.1 was 5.27 ± 1.69 μM (n ≥ 4), indicating ~11-fold 
selectivity for K2P18.1.
3.4 Molecular Determinants Critical for K2P18.1 Sensitivity to Loratadine
Structural modeling has been performed for mouse K2P18.1 and was used to determine key 
residues for inhibitory activity of multiple known, nonspecific K2P18.1 inhibitors including 
lidocaine (Kim et al., 2013). The two residues identified as important for inhibition were 
F156 and F364, which are present in the 2nd and 4th transmembrane domains of K2P18.1 
respectively. In human K2P18.1, the corresponding residues, F145 and F352, are conserved. 
To determine whether these residues are also critical for lidocaine inhibition on human 
K2P18.1, and to examine whether loratadine activity is dependent on these residues, the 
Bruner et al. Page 6













effects of lidocaine and loratadine were examined on the F145A/F352A double mutant 
K2P18.1 (mutK2P18.1).
First, the non-selective K2P18.1 blocker lidocaine was used to determine the importance of 
the F145 and F352 residues for inhibitor activity. Similar to the mouse K2P18.1 mutant, the 
human mutant formed functional channels when expressed in HEK293 cells. The Tl+ flux 
assay revealed a rightward shift of the IC50 to 11.6 ± 7.1 mM for lidocaine against 
mutK2P18.1 (Fig. 4E). Whole-cell patch clamp recording showed a significant reduction in 
lidocaine effectiveness against mutK2P18.1 compared to wild type, with 1 mM lidocaine 
inhibiting mutK2P18.1 current by only 18.2 ± 5.8% (Fig. 4, B and D, n=5). This is in 
agreement with earlier data in which F156A/F364A double mutant mouse K2P18.1 was 
inhibited by 1 mM lidocaine only 20 ± 15%, significantly less than the 83 ± 5% inhibition of 
the wild type channel (Kim et al., 2013), and confirms the role of the F145 and F352 
residues of human K2P18.1 for lidocaine activity.
Next, mutK2P18.1 was used to establish whether loratadine’s inhibitory activity is also 
dependent on the F145 and F352 residues. When measured in the Tl+ flux assay, loratadine 
failed to reach 50% inhibition against mutK2P18.1 at the maximally tested concentration of 
150 μM, suggesting at least 50 fold lower potency compared to wtK2P18.1 (Fig. 4F). Whole-
cell patch clamp recording further validated a significantly reduced inhibition, with 10 μM 
loratadine inhibiting mutK2P18.1 current by 3.9 ± 13.3% (Fig. 4, B and D, n=4). Taken 
together, these data demonstrate that the F145 and F352 residues on human K2P18.1 are 
among key molecular determinants for the inhibitory activity of loratadine.
4. Discussion
The KCNK18 gene was first cloned in 2003 from human spinal cord (Sano et al., 2003). At 
the time, the K2P18.1 channel was identified as a member of the K2P family expressed in the 
spinal cord with low sequence similarity yet somewhat comparable pharmacology to other 
family members. More recently, K2P18.1 gained considerable interest when a dominant-
negative mutation in KCNK18 was directly linked to a subset of patients with familial 
migraine with aura. However, K2P18.1 physiology in native systems is still poorly 
understood, and one of the roadblocks to advancing this understanding lies with the lack of 
quality pharmacological tools for probing its activity.
Here we developed an effective assay and screened the commercially available library of 
bioactive compounds (LOPAC) to search for modulators of K2P18.1 channel activity. To 
gain an initial insight into specificity for K2P18.1, this library was also screened against 
another member of the K2P family, K2P9.1. From the identified hits, 26 inhibitors and 8 
activators were verified with selectivity for K2P18.1 over K2P9.1. Admittedly, to better 
characterize the specificity one important future direction is to establish its selectivity profile 
by systematically testing these compounds against a range of other targets including but not 
limited to other K2P family members. Of note, a sequence alignment of all 15 K2P family 
members reveals that the F145 and F352 residues on K2P18.1 critical for inhibition by 
loratadine are completely unique to K2P18.1 (Fig. S3). The K2P18.1-specific residues critical 
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for drug sensitivity provide a plausible molecular explanation for specificity for K2P18.1 
over K2P9.1 as reported here, and may hold true for other family members in future studies.
Among the identified activators, six have reported muscarinic acetylcholine receptor agonist 
activity. As K2P18.1 is calcium-activated, these compounds are very likely activating 
K2P18.1 via stimulation of endogenous M3 muscarinic acetylcholine receptors present on 
HEK293 cells (Pierce et al., 2002; Luo et al., 2008). Another identified activator, spiperone 
hydrochloride, is known to elevate intracellular calcium levels in HEK293 cells (Lu and 
Carson, 2009). Phorbol 12-myristate 13-acetate (PMA) is an activator of protein kinase C 
and has been previously shown to activate K2P18.1 through kinase activity (Rahm et al., 
2012). Other interesting compounds include those that appear to have higher selectivity for 
K2P9.1 (Fig. 1C). Some compounds seem to activate K2P9.1 yet inhibit or have no effect on 
K2P18.1. These actives, while not in the scope of the present studies, are worth further 
characterization in future investigations.
In addition to the identification of a series of tool compounds, this work has also begun to 
provide insights into the mechanism of action by the antihistamine loratadine. The effects of 
loratadine were examined using the Tl+ flux assay and patch clamp recording. The recording 
protocol was adapted from the literature for proper comparison of compound pharmacology. 
The ramp from −120 mV to +60 mV allowed for visualization of characteristic K2P18.1 
outward rectification and assessment of recording quality, while the step to +60 mV 
provided sufficient time resolution for accurate measurement and quantification. Only 
recordings with current amplitude ≥1000 pA at +60 mV and a consistent reversal potential 
near the expected −85mV were used for analysis. It is important to note that the Tl+ flux 
assay and patch clamp recording yielded comparable IC50 values with respect to loratadine 
inhibition, which argues for the validity of the Tl+ based high throughput screening assay. 
This compatibility therefore justifies future use of this assay for larger HTS campaigns to 
discover other chemical structures with suitable pharmacology and drugability.
Both loratadine and the known K2P18.1 blocker lidocaine showed equal levels of 
modulatory activity independent of channel activation by carbachol-induced signaling. This 
suggests that loratadine, regardless of its mechanism of action, is acting downstream from 
the carbachol pathway. Based on a homology model, two key residues, F156 and F364 in 
mouse K2P18.1 and conserved as F145 and F352 in human K2P18.1, have been shown to 
face the central cavity and interact with the K2P18.1 blockers quinine, propafenone, and 
lidocaine via π-π interactions (Kim et al., 2013). Mutating these residues to alanine in mouse 
K2P18.1 resulted in diminished inhibition by all three compounds. In this study, we 
generated the equivalent mutant human K2P18.1 channel, F145A/F352A. Indeed, lidocaine 
showed significantly reduced inhibitory activity against the mutant channel. Loratadine 
showed an even more dramatic reduction in activity against the mutant as compared to wild 
type. The differential extents affected by the mutation may be the molecular basis for the 
target selectivity. Based on the earlier modeling and the data here, a plausible model would 
involve F145 and F352 residues being the key residues for mediating binding of K2P18.1 
inhibitors including loratadine. The mechanism of loratadine is less likely through allosteric 
effects but rather a direct block of the permeation pathway. While more work is needed to 
understand the mechanism of interaction and specificity, based on its pharmacology reported 
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here, loratadine is significantly more potent than both lamotrigine and isobutylalkenyl amide 
(IBA), suggesting it may serve as a more effective inhibitor probe of K2P18.1 activity. 
Although loratadine has been shown to inhibit other potassium channels, including human 
ether-a-go-go-related gene (hERG) and Kv1.5, it would certainly serve as a useful tool in 
DRG and TG neurons where K2P18.1 is most abundantly expressed (Kang and Kim, 2006; 
Lafreniere et al., 2010; Lacerda et al., 1997; Crumb, 2000).
In summary, we report the identification and validation of several small molecules that 
modulate K2P18.1 channel activity specifically over K2P9.1. In particular, a large number of 
channel inhibitors were identified, at least one of which likely directly blocks the channel 
pore. Furthermore, two residues, F145 and F352, specifically conserved in K2P18.1, are key 
determinants for drug sensitivity. The compounds identified here may be useful for probing 
native K2P18.1 in order to identify its precise physiological role.
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Identification of K2P18.1 modulators by a thallium based screening of LOPAC. (A) 
Flowchart outlining the screening and characterization process. (B) and (C) Scatter plots 
showing the results of the primary and counter screens for activators (B) and inhibitors (C) 
of K2P18.1 channel activity. Normalized activity against both K2P18.1 and K2P9.1 at 100 s 
(inhibitors) or 50 s (activators) is plotted. Filled circles indicate compounds chosen for 
validation assay. Loratadine is labeled.
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Structures and potencies of identified K2P18.1 inhibitors.
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Lidocaine and loratadine inhibit K2P18.1 channel activity independent of activation state. 
(A) and (B) Concentration-response curves for K2P18.1 inhibition by lidocaine (A) and 
loratadine (B) as measured in the presence and absence of 30 μM carbachol. Fluorescence 
intensity was measured as a readout of Tl+ flux. Each curve was normalized to the value of 
the lowest compound concentration. Each point is mean ± S.D. n = 4 for both compounds.
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Comparison of K2P18.1 inhibitors on the wild type and mutant channels. (A) and (B) 
Representative traces for inhibition of wtK2P18.1 (A) and mutK2P18.1 (B) by lidocaine and 
loratadine. The holding potential for recording was −80 mV and K2P18.1 current was 
elicited by a ramp protocol from −120 mV to +60 mV. (C) Concentration-response 
inhibition of loratadine on wtK2P18.1 and K2P9.1 activity. Currents amplitudes were 
measured at +60 mV. Each point is mean ± S.D. of ≥ 4 measurements. (D) Summary of 
wtK2P18.1 and mutK2P18.1 inhibition by lidocaine and loratadine. Currents were measured 
at +60 mV. Each bar is mean ± S.D. of ≥ 4 measurements. *** indicates statistical 
significance (P < 0.001) (E) and (F) Concentration-response curves for wtK2P18.1 and 
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mutK2P18.1 inhibition by lidocaine (E) and loratadine (F). Fluorescence intensity was 
measured as a readout of Tl+ flux. Each curve was normalized to the value of the lowest 
compound concentration. n = 3 for lidocaine, n = 4 for loratadine.
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